YAP-1 as prognostic marker for immunochemotherapy response in SCLC patients

#4068

Introduction: Small-cell lung cancer (SCLC) represents about 15% of all lung cancers and is an exceptionally lethal malignancy for which more effective therapies are urgently needed. Previous studies have classified SCLC patients by RNA-sequencing (RNA-seq) clustering analysis to identify who could benefit from immune checkpoint blockades.

Aim(s): In our study, we aimed to explore whether YES-associated protein 1 (YAP-1) could identify SCLC patients with stable benefits from immunochemotherapy as potential biomarker.

Materials and methods: We enrolled 36 patients with SCLC received treatment (chemotherapy vs immunochemotherapy). Associations with clinico-pathological features and immunohistochemical markers were evaluated; subsequently obtained data were correlated with Overall Survival and Progression Free Survival.

Conference:

Presenting Author:

Authors: Sabella G,

Keywords: neuroendocrine, immunochemotherapy, SCLC, YAP-1,